Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1522803

Cover Image

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1522803

Global Blood Glucose Monitoring System Market Size study, by Device Type, by Modality, by Type, by Patient Type, by Distribution Channel and Regional Forecasts 2022-2032

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (Enterprise License)
USD 6250

Add to Cart

Global Blood Glucose Monitoring System Market is valued at approximately USD 16.46 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2024-2032. Blood glucose monitoring devices are essential tools for patients managing type 1 and type 2 diabetes, enabling them to measure glucose levels in their blood accurately. The increasing prevalence of diabetes worldwide has significantly expanded the patient pool requiring regular glucose monitoring. Advances in device technology and supportive reimbursement policies are anticipated to fuel market growth.

The Institute for Health Metrics and Evaluation (IHME) estimated in 2023 that the global prevalence of diabetes stands at 6.1%, making it one of the top ten leading causes of death and disability. In April 2023, the Medicare program expanded access to continuous glucose monitoring (CGM) systems, removing previous requirements for multiple daily insulin injections. The COVID-19 pandemic further accelerated market growth as diabetic patients sought home-based monitoring solutions. Key players have reported increased revenue in diabetes care, highlighting the pandemic's positive impact on the market.

The market is experiencing robust growth due to the rising penetration of CGM systems. These systems offer real-time monitoring, minimal invasiveness, and precise results, which are shifting the preference of healthcare providers and patients towards CGM over traditional self-monitoring blood glucose (SMBG) systems. For instance, Abbott reported an increase in Freestyle Libre users from 4.5 million in 2022 to 5.0 million in 2023. Companies in Europe are developing non-invasive CGM devices, further driving market growth. The growing prevalence of diabetes, especially in emerging countries, has expanded the patient pool requiring blood glucose monitoring. Urbanization and sedentary lifestyles are major contributors to the rising diabetes rates. The International Diabetes Federation estimated in 2021 that around 537 million adults had diabetes, with significant contributions from China, India, the U.S., Brazil, and Mexico. The adoption of CGM devices is increasing, with over 7 million people using them for daily diabetes management worldwide. This, along with favorable reimbursement policies and new product introductions, is fueling market growth from 2024-2032. However, the high cost of CGM systems limits their adoption in emerging countries. The costs associated with these devices, including sensors, transmitters, and consumables, are a significant barrier.

The key regions considered for the Global Blood Glucose Monitoring System Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global Blood Glucose Monitoring System Market in terms of revenue. The market growth in the region is being attributed to factors including the rising number of diabetes patients, growing adoption of advanced medical devices, and high per capita medical expenses. Whereas, the market in Europe is anticipated to grow at the fastest rate over the forecast period fueled by heightened awareness of diabetes management and the rising demand for home monitoring systems.

Major market players included in this report are:

  • Abbott (U.S.)
  • B. Braun SE (Germany)
  • Dexcom, Inc. (U.S.)
  • Ascensia Diabetes Care Holdings AG (Switzerland)
  • Medtronic (Ireland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Terumo Corporation (Japan)
  • LifeScan IP Holdings, LLC (U.S.)
  • Senseonics (U.S.)
  • Roche Holding AG
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Johnson & Johnson
  • Ypsomed AG
  • ARKRAY, Inc.

The detailed segments and sub-segment of the market are explained below:

By Device Type:

  • Continuous Glucose Monitoring Systems
  • Self-Monitoring Blood Glucose Systems

By Modality:

  • Wearable
  • Non-wearable

By Type:

  • Non-invasive
  • Invasive

By Patient Type:

  • Type-1 Diabetes
  • Type-2 Diabetes

By Distribution Channel:

  • Institutional Sales
  • Retail Sales

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Blood Glucose Monitoring System Market Executive Summary

  • 1.1. Global Blood Glucose Monitoring System Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Device Type
    • 1.3.2. By Modality
    • 1.3.3. By Type
    • 1.3.4. By Patient Type
    • 1.3.5. By Distribution Channel
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Blood Glucose Monitoring System Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Blood Glucose Monitoring System Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rising Prevalence of Diabetes
    • 3.1.2. Increasing Penetration of Continuous Glucose Monitoring (CGM) Systems
  • 3.2. Market Challenges
    • 3.2.1. High Cost Associated with CGM Systems
    • 3.2.2. Transportation Concerns Related to CO2
  • 3.3. Market Opportunities
    • 3.3.1. Adoption of CCS Technology for CO2 Procurement
    • 3.3.2. Increasing Use in Medical and Food & Beverage Industries

Chapter 4. Global Blood Glucose Monitoring System Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Blood Glucose Monitoring System Market Size & Forecasts by Device Type 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Blood Glucose Monitoring System Market: Device Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Continuous Glucose Monitoring Systems
    • 5.2.2. Self-Monitoring Blood Glucose Systems

Chapter 6. Global Blood Glucose Monitoring System Market Size & Forecasts by Modality 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Blood Glucose Monitoring System Market: Modality Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Wearable
    • 6.2.2. Non-wearable

Chapter 7. Global Blood Glucose Monitoring System Market Size & Forecasts by Type 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Blood Glucose Monitoring System Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Non-invasive
    • 7.2.2. Invasive

Chapter 8. Global Blood Glucose Monitoring System Market Size & Forecasts by Patient Type 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Global Blood Glucose Monitoring System Market: Patient Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 8.2.1. Type-1 Diabetes
    • 8.2.2. Type-2 Diabetes

Chapter 9. Global Blood Glucose Monitoring System Market Size & Forecasts by Distribution Channel 2022-2032

  • 9.1. Segment Dashboard
  • 9.2. Global Blood Glucose Monitoring System Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 9.2.1. Institutional Sales
    • 9.2.2. Retail Sales

Chapter 10. Global Blood Glucose Monitoring System Market Size & Forecasts by Region 2022-2032

  • 10.1. North America Blood Glucose Monitoring System Market
    • 10.1.1. U.S. Blood Glucose Monitoring System Market
      • 10.1.1.1. Device Type breakdown size & forecasts, 2022-2032
      • 10.1.1.2. Modality breakdown size & forecasts, 2022-2032
      • 10.1.1.3. Type breakdown size & forecasts, 2022-2032
      • 10.1.1.4. Patient Type breakdown size & forecasts, 2022-2032
      • 10.1.1.5. Distribution Channel breakdown size & forecasts, 2022-2032
    • 10.1.2. Canada Blood Glucose Monitoring System Market
  • 10.2. Europe Blood Glucose Monitoring System Market
    • 10.2.1. U.K. Blood Glucose Monitoring System Market
    • 10.2.2. Germany Blood Glucose Monitoring System Market
    • 10.2.3. France Blood Glucose Monitoring System Market
    • 10.2.4. Spain Blood Glucose Monitoring System Market
    • 10.2.5. Italy Blood Glucose Monitoring System Market
    • 10.2.6. Rest of Europe Blood Glucose Monitoring System Market
  • 10.3. Asia-Pacific Blood Glucose Monitoring System Market
    • 10.3.1. China Blood Glucose Monitoring System Market
    • 10.3.2. India Blood Glucose Monitoring System Market
    • 10.3.3. Japan Blood Glucose Monitoring System Market
    • 10.3.4. Australia Blood Glucose Monitoring System Market
    • 10.3.5. South Korea Blood Glucose Monitoring System Market
    • 10.3.6. Rest of Asia Pacific Blood Glucose Monitoring System Market
  • 10.4. Latin America Blood Glucose Monitoring System Market
    • 10.4.1. Brazil Blood Glucose Monitoring System Market
    • 10.4.2. Mexico Blood Glucose Monitoring System Market
    • 10.4.3. Rest of Latin America Blood Glucose Monitoring System Market
  • 10.5. Middle East & Africa Blood Glucose Monitoring System Market
    • 10.5.1. Saudi Arabia Blood Glucose Monitoring System Market
    • 10.5.2. South Africa Blood Glucose Monitoring System Market
    • 10.5.3. Rest of Middle East & Africa Blood Glucose Monitoring System Market

Chapter 11. Competitive Intelligence

  • 11.1. Key Company SWOT Analysis
  • 11.2. Top Market Strategies
  • 11.3. Company Profiles
    • 11.3.1. Abbott (U.S.)
      • 11.3.1.1. Key Information
      • 11.3.1.2. Overview
      • 11.3.1.3. Financial (Subject to Data Availability)
      • 11.3.1.4. Product Summary
      • 11.3.1.5. Market Strategies
    • 11.3.2. B. Braun SE (Germany)
    • 11.3.3. Dexcom, Inc. (U.S.)
    • 11.3.4. Ascensia Diabetes Care Holdings AG (Switzerland)
    • 11.3.5. Medtronic (Ireland)
    • 11.3.6. F. Hoffmann-La Roche Ltd (Switzerland)
    • 11.3.7. Terumo Corporation (Japan)
    • 11.3.8. LifeScan IP Holdings, LLC (U.S.)
    • 11.3.9. Senseonics (U.S.)
    • 11.3.10. Roche Holding AG
    • 11.3.11. Sanofi S.A.
    • 11.3.12. Novo Nordisk A/S
    • 11.3.13. Johnson & Johnson
    • 11.3.14. Ypsomed AG
    • 11.3.15. ARKRAY, Inc.

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!